emerging therapies for managing complement 3 glomerulopathy
Published 2 years ago • 916 plays • Length 20:30Download video MP4
Download video MP3
Similar videos
-
28:36
new horizons in treating complement-associated kidney diseases
-
1:41
complement 3 glomerulopathy market size was ~usd 35 million in 2023
-
5:40
understanding mpgn and c3 glomerulopathy
-
28:59
navigating the rapidly evolving landscape of glomerular kidney disease management
-
28:08
optimizing maintenance immunosuppressive therapy in kidney transplantation
-
2:48
how doctors diagnose and treat c3g and ic-mpgn | rare disease | american kidney fund
-
29:48
chronic active antibody mediated rejection targeting il 6 to improve outcomes in kidney transplant
-
58:31
c3g and primary ic-mpgn: complement system driven glomerulopathies
-
2:29
combining menin/flt3/bcl2 inhibition as a treatment approach in flt3/npm1 double mutated aml
-
58:30
the potential of her2-, her3-, and trop2-targeted therapies to address unmet needs in advanced nsclc
-
1:26
preclinical safety and efficacy of cd123-nk cell engager in r/r aml
-
2:43
phase i dose escalation of imc-f106c - first prame × cd3 immtac bispecific protein in solid tumors
-
41:16
c3 glomerulopathy - erknet webinar with marina vivarelli
-
1:17
efficacy & safety of standard of care cilta-cel in r/r multiple myeloma
-
2:08
crenolanib plus 7 3 chemotherapy in adults with newly diagnosed flt3-mutated aml.
-
1:13
get comfortable with 3m™ cavilon™ no sting barrier film
-
3:20
phase i trial of a bcma-cd3 bispecific antibody in r/r myeloma
-
1:29
bispecific bcma-cd3 antibody teclistamab is efficacious and tolerable in r/r mm
-
1:29
karmma-3: qol of patients with tce r/r myeloma treated with ide-cel vs standard regimens